Skip to main content
Clinical Trials/DRKS00025594
DRKS00025594
Completed
N/A

Reduction of care-related risks for older patients during and post acute hospital care - ReduRisk

niversitätsklinikum Freiburg0 sites589 target enrollmentAugust 9, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Functional decline, immobility, falls, delirium and rehospitalization
Sponsor
niversitätsklinikum Freiburg
Enrollment
589
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • acute inpatients \= 70 years of age, increased risk for functional decline, immobility, falls, delirium, or rehospitalisation, informed consent

Exclusion Criteria

  • Patients receiving palliative care in the final phase.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Pro-active care for the older people at risk for functional decline: Screening for vulnerability and effectiveness of a subsequent guided care plan in primary careeerstelijns ouderengeneeskundeolder people with multiple problemsvulnerable elderly
NL-OMON33008eids Universitair Medisch Centrum10,000
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-BESaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002272-27-ATSaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-PTSaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible forhigh-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma infirst Relapse or Progression by adding Nivolumab to Gemcitabine,Oxaliplatin plus Rituximab in case of B-cell lymphoma.
EUCTR2016-002272-27-PLSaarland University388